Viela Bio (USA) announced the start of the company’s first clinical trial, a phase 1, first-in-human clinical trial of VIB9600, which is being developed for the treatment of adult patients with immune mediated diseases.
Following the completion of the pre-clinical studies, Viela Bio filed the investigational new drug application(IND) to FDA and the U.S. regulator approved the phase I trial that will be executed in collaboration with CTI Clinical Trial & Consulting as the contract research organization.
VIB9600 or placebo will be administered to a maximum of 64 healthy adult volunteers enrolled in up to eight groups to evaluate the safety and tolerability of single and multiple doses of VIB9600. Analyses of the differences between the groups will inform decisions for future studies.
Headquartered in Gaithersburg, Maryland (USA), Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases by selectively targeting shared critical pathways that are the root cause of disease.